KPV vs LL-37: Anti-Inflammatory vs Antimicrobial
Here is how these two compounds compare — based on published research, not marketing claims.
KPV
27
Indexed Studies
Animal Studies
Evidence Level
None
Human Trials
Not Approved
FDA Status
LL-37
3096
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
KPV and LL-37 are both studied for immune function, but they solve different problems. KPV is an anti-inflammatory tripeptide that turns down the inflammatory alarm. LL-37 is an antimicrobial peptide that kills bacteria and disrupts biofilms directly. One calms the immune system. The other arms it. Both are early in clinical development.
Key Differences
| Attribute | KPV | LL-37 |
|---|---|---|
| Evidence Level | Preclinical | Animal Studies |
| Category | Alpha-MSH Fragment | Cathelicidin |
| Human Data | No human clinical studies. All evidence is preclinical. PSI rates L1. | Primarily preclinical. Extensive mechanistic research. Very limited human therapeutic studies. PSI rates L2. |
| Safety Profile | Very limited data. As a short endogenous peptide fragment, theoretical safety is favorable. | Endogenous — your body makes it. Limited therapeutic dose safety data. |
| Key Limitations | Zero human data. Small research base. General mechanism, not disease-specific. | Stability challenges for therapeutic use. Most research is in vitro. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
KPV
A three-amino-acid fragment of alpha-MSH. Inhibits NF-kB — the master switch for inflammatory gene expression. Reduces inflammation at the molecular level without suppressing the immune system's ability to fight pathogens.
LL-37
Human antimicrobial peptide that physically disrupts bacterial membranes and biofilms. Also recruits immune cells to infection sites. Your body produces it as part of innate defense. Think of it as a molecular weapon that punches holes in bacteria.
Different weapons for different battles. KPV turns off the inflammatory alarm by blocking NF-kB. LL-37 kills the invaders directly by disrupting their cell membranes. KPV is anti-inflammatory — it reduces the damage your own immune response can cause. LL-37 is antimicrobial — it eliminates the pathogens that triggered the response.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 3,123 indexed studies. Here are the key findings.
LL-37 is L2 with significantly more published research (3,000+ papers vs KPV's ~27). However, both have minimal human therapeutic data. LL-37's research advantage is primarily in mechanistic understanding, not clinical validation.
For inflammation reduction without immunosuppression, KPV has the more targeted mechanism.
For antimicrobial applications or biofilm-related conditions, LL-37 is the relevant compound.
For gut inflammation specifically, KPV has some preclinical data but no human validation.
For evidence depth, LL-37 has vastly more published research, though most is preclinical.
Key Limitations
- •Both are early-stage with minimal human data.
- •KPV has no human studies at all.
- •LL-37's research is extensive but primarily in vitro.
- •Direct comparison is premature given both compounds' early development status.
PSI Verdict
SUPPORTED BY EVIDENCE
KPV inhibits NF-kB-mediated inflammation in preclinical models. LL-37 demonstrates potent antimicrobial and biofilm-disrupting activity across thousands of studies. Both are endogenous human peptides.
NOT YET ESTABLISHED
Neither has human clinical trial data supporting therapeutic use. KPV's anti-inflammatory effects have not been validated in humans. LL-37's therapeutic potential is limited by delivery and stability challenges.
CONFIDENCE LEVEL
Low for both as therapeutic interventions. LL-37 has more scientific depth. KPV has a cleaner anti-inflammatory narrative. Neither is close to clinical recommendation.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
KPV
"KPV healed my leaky gut"Insufficient evidence
"KPV works orally — you don't need to inject it"Plausible mechanism
LL-37
"LL-37 cured my chronic infection"Insufficient evidence
"LL-37 is the body's natural antibiotic"Supported by evidence
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
KPV
Very limited data. As a short endogenous peptide fragment, theoretical safety is favorable.
LL-37
Endogenous — your body makes it. Limited therapeutic dose safety data.
Both are endogenous peptides, which is theoretically favorable. Neither has formal clinical safety data at therapeutic doses. LL-37 faces stability and delivery challenges that limit therapeutic development.
WHAT THE RESEARCH SUGGESTS
Both are interesting early-stage immune peptides targeting different problems. LL-37 has more research behind it. KPV has a more novel anti-inflammatory mechanism. Neither is ready for confident clinical recommendations.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.